Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 3/20 | 0.35 |
| ▸ | CTSB | P07858 | 3/20 | 0.35 |
| ▸ | CTSH | P09668 | 2/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levopropylhexedrine SCHEMBL20780004 | 1.00 | CTSK (0.42) | CTSKSIGMAR1MEN1KMT2ACTSL | |
| Propylhexedrine SCHEMBL28537 | 1.00 | CTSK (0.42) | CTSKSIGMAR1MEN1KMT2ACTSL | |
| Propylhexedrine SCHEMBL28890426 | 0.98 | CTSK (0.41) | CTSKSIGMAR1MEN1KMT2ACTSL | |
| Propylhexedrine SCHEMBL4900116 | 0.98 | CTSK (0.41) | CTSKSIGMAR1MEN1KMT2ACTSL | |
| Cyclopentamine SCHEMBL13479599 | 0.98 | CTSK (0.40) | CTSKSIGMAR1MEN1KMT2ACTSL | |
| Cyclopentamine SCHEMBL249708 | 0.98 | CTSK (0.40) | CTSKSIGMAR1MEN1KMT2ACTSL | |
| Cyclopentamine SCHEMBL317336 | 0.95 | CTSK (0.39) | CTSKSIGMAR1MEN1KMT2ACTSL | |
| SCHEMBL27308544 | 0.93 | — | — | |
| SCHEMBL22627190 | 0.81 | CTSK (0.32) | CTSK | |
| SCHEMBL23241391 | 0.79 | OPRK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| US-20200060997-A1 | TARR Receptor Agonists for Sexual Dysfunction | JOHN MCCOY | 2020-02-27 | — | — | US | claimed |
| EP-3366306-A2 | USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-08-29 | — | — | EP | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1497272-A4 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM LLC (US) | 2007-02-07 | — | — | EP | claimed |
| US-7129378-B2 | Method of preparing amine stereoisomers | APSINTERM, LLC (US) | 2006-10-31 | — | — | US | claimed |
| US-20050165240-A1 | Method of preparing amine stereoisomers | APSINTERM, LLC | 2005-07-28 | — | — | US | claimed |
| EP-1497272-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | Apsinterm, LLC. (US) | 2005-01-19 | — | — | EP | claimed |
| WO-2003091207-A2 | METHOD OF PREPARING AMINE STEREOISOMERS | APSINTERM, LLC. (US) | 2003-11-06 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2026106796-A1 | SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS | FOLLEA INTERNATIONAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-6288040-B1 | CARRIER SURFACE BONDED TO RECOGNITION PROTEINS; DRUG DELIVERY; CENTRAL NERVOUS SYSTEM DISORDERS | DSS DRUG DELIVERY SERVICE GESELLSCHAFT ZUR FORDERUNG DER FOSHUNG IN PHAMAZEUTISCHER TECHNOLOGI UND BIOPHARMAZIE MBH (DE) | 2001-09-11 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CTSK 736/4885SIGMAR1 3110/4885MEN1 2172/4885 |
| US-20050165240-A1 | Method of preparing amine stereoisomers | SRM, TST, SMOX | CTSK 4526/4885SIGMAR1 411/4885MEN1 2372/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CTSK 736/4885SIGMAR1 3110/4885MEN1 2172/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CTSK 736/4885SIGMAR1 3110/4885MEN1 2172/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CTSK 736/4885SIGMAR1 3110/4885MEN1 2172/4885 |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | DYRK4, DYRK2, STRA6 | CTSK 1429/4885SIGMAR1 4868/4885MEN1 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.